A Pragmatic Approach to Immunity & Respiratory Viral Infections.
作者信息
Born Todd A
出版信息
Integr Med (Encinitas). 2020 Oct;19(5):8-15.
Abstract
摘要
相似文献
1
A Pragmatic Approach to Immunity & Respiratory Viral Infections.一种针对免疫与呼吸道病毒感染的实用方法。
Integr Med (Encinitas). 2020 Oct;19(5):8-15.
2
Long-Term Respiratory Consequences of Early-Life Respiratory Viral Infections: A Pragmatic Approach to Fundamental Questions.婴幼儿期呼吸道病毒感染的长期呼吸后果：基本问题的实用方法。
J Allergy Clin Immunol Pract. 2022 Mar;10(3):664-670. doi: 10.1016/j.jaip.2021.12.005. Epub 2021 Dec 20.
3
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病（NO COVID-19）实用开放性标签研究，评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
4
Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.黏膜灭活疫苗 MV130 诱导的训练性免疫可预防实验性病毒性呼吸道感染。
Cell Rep. 2022 Jan 4;38(1):110184. doi: 10.1016/j.celrep.2021.110184.
5
Respiratory viral infections and host responses; insights from genomics.呼吸道病毒感染与宿主反应；基因组学的见解
Respir Res. 2016 Nov 21;17(1):156. doi: 10.1186/s12931-016-0474-9.
6
Enhancing immunity in viral infections, with special emphasis on COVID-19: A review.增强病毒感染中的免疫力，特别关注 COVID-19：综述
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):367-382. doi: 10.1016/j.dsx.2020.04.015. Epub 2020 Apr 16.
7
Pulmonary immunity to viruses.肺部对病毒的免疫
Clin Sci (Lond). 2017 Jun 30;131(14):1737-1762. doi: 10.1042/CS20160259. Print 2017 Jul 15.
8
Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.SARS-CoV-2 的早期进化与跨冠状病毒免疫。
mSphere. 2020 Sep 2;5(5):e00622-20. doi: 10.1128/mSphere.00622-20.
9
Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.基于Toll样受体激动剂的呼吸道病毒性疾病治疗方法：跳出细胞的思考
Eur Respir Rev. 2022 May 4;31(164). doi: 10.1183/16000617.0274-2021. Print 2022 Jun 30.
10
Cell-mediated immunity in humans during viral infection: dermal hypersensitivity and in vitro lymphocyte proliferation during mild viral respiratory infections.病毒感染期间人类的细胞介导免疫：轻度病毒性呼吸道感染期间的皮肤超敏反应和体外淋巴细胞增殖。
Infect Immun. 1974 Oct;10(4):757-61. doi: 10.1128/iai.10.4.757-761.1974.
引用本文的文献
1
Chronobiological Efficacy of Combined Therapy of Pelargonium Sidoides and Melatonin in Acute and Persistent Cases of COVID-19: A Hypothetical Approach.南非钩麻和褪黑素联合治疗急性和持续性 COVID-19 的时间生物学疗效：一种假设方法。
Adv Exp Med Biol. 2023;1412:427-442. doi: 10.1007/978-3-031-28012-2_23.
本文引用的文献
1
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
2
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.免疫功能低下患者持续性 COVID-19 经瑞德西韦两疗程治疗暂时起效
J Infect Dis. 2020 Sep 1;222(7):1103-1107. doi: 10.1093/infdis/jiaa446.
3
The COVID-19 Cytokine Storm; What We Know So Far.《COVID-19 细胞因子风暴：目前我们所了解的》。
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
4
Antibody tests for identification of current and past infection with SARS-CoV-2.用于识别当前和既往感染新型冠状病毒2的抗体检测。
Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652.
5
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的临床和免疫学评估。
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
6
Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020.2019 年冠状病毒病病例监测-美国，2020 年 1 月 22 日-5 月 30 日。
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765. doi: 10.15585/mmwr.mm6924e2.
7
Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters.评估多个全球疫情中心 COVID-19 病例的大量漏报和漏检。
Pulmonology. 2021 Mar-Apr;27(2):110-115. doi: 10.1016/j.pulmoe.2020.05.015. Epub 2020 Jun 6.
8
Cytokine storm induced by SARS-CoV-2.由 SARS-CoV-2 引起的细胞因子风暴。
Clin Chim Acta. 2020 Oct;509:280-287. doi: 10.1016/j.cca.2020.06.017. Epub 2020 Jun 10.
9
Antibody responses to SARS-CoV-2 in patients with COVID-19.新型冠状病毒肺炎（COVID-19）患者的 SARS-CoV-2 抗体反应。
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
10
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.药理角度：甘草酸可能是治疗 COVID-19 的有效药物。
Int J Antimicrob Agents. 2020 Jun;55(6):105995. doi: 10.1016/j.ijantimicag.2020.105995. Epub 2020 Apr 24.
Zotero 插件